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ABSTRACT
Antitumor immunity can be enhanced by the coordinated release and delivery of antigens and immune-
stimulating agents to antigen-presenting cells via biodegradable vaccine carriers. So far, encapsulation of
TLR ligands and tumor-associated antigens augmented cytotoxic T cell (CTLs) responses. Here, we
compared the efficacy of the invariant NKT (iNKT) cell agonist a-galactosylceramide (a-GalCer) and TLR
ligands (R848 and poly I:C) as an adjuvant for the full length ovalbumin (OVA) in PLGA nanoparticles. We
observed that OVA+a-GalCer nanoparticles (NP) are superior over OVA+TLR-L NP in generating and
stimulating antigen-specific cytotoxic T lymphocytes without the need for CD4C T cell help. Not only a 4-
fold higher induction of antigen-specific T cells was observed, but also a more profound IFN-g secretion
was obtained by the addition a-GalCer. Surprisingly, we observed that mixtures of OVA containing NP
with a-GalCer were ineffective, demonstrating that co-encapsulation of both a-GalCer and antigen within
the same nanoparticle is essential for the observed T cell responses. Moreover, a single immunization with
OVA+a-GalCer NP provided substantial protection from tumor formation and even delayed the growth of
already established tumors, which coincided with a prominent and enhanced antigen-specific CD8C T cell
infiltration. The provided evidence on the advantage of antigen and a-GalCer coencapsulation should be
considered in the design of future nanoparticle vaccines for therapeutic purposes.






Current cancer immunotherapy strategies are aimed at the gen-
eration of reliable and long-lasting immune responses against
tumor antigens. In this context, CTLs have received most of the
attention due to their ability of specifically killing tumor cells,
as well as generating a memory phenotype preventing recur-
rence. Various pre-requisites have to be met for a full-blown
activation of CTLs such as cross-priming by an activated anti-
gen-presenting dendritic cell (DC) and a stimulatory milieu
consisting of helper T cells (Th cells), NK cells and macro-
phages which ensure a favorable cross-talk through secreted
cytokines.1,2 Therefore, when designing a new therapeutic vac-
cine-based strategy, it is important to include adequate stimuli
in addition to antigen to activate the complete immune
machinery.
Natural Killer T cells (NKT cells) are specialized immune
cells that share the expression of a T cell receptor together with
NK cell receptors and have the ability to bridge the innate with
the adaptive immunity by the swift production of pro- and
anti-inflammatory cytokines upon activation.3,4 The most
studied subtype of NKT cells are the invariant TCR bearing
NKT cells (iNKT cells) cells that recognize glycolipid antigens
such as a-GalCer presented by CD1d molecules on antigen pre-
senting cells (APCs). This recognition by iNKT cells stimulate
both iNKT cells and APCs which in turn, induce the secretion
of various pro-inflammatory cytokines and activate a broad
spectrum of immune cells against the tumor.5 Among these
IFN-g and IL-12 are the most abundant, which can switch the
immune response in favor of a Th1 driven response. Addition-
ally, the CD40–CD154 ligation during the presentation of gly-
colipids to iNKT cells evokes DC maturation up-regulating
other co-stimulatory ligands.6,7 Based on these characteristics,
iNKT cells have been called the ‘swiss army knife of the
immune system’ and harnessing of iNKT cells should be con-
sidered in any antitumor vaccination modality.8
a-GalCer has been regarded as a potent vaccine adjuvant.4
Especially enhanced antigen-specific antitumor CD4C and
CD8C T cell responses were documented in combination with
the widely used OVA antigen.9-11 Type I iNKT cell activation
by systemic administration of a-GalCer was shown to protect
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mice from chemical or oncogene-induced primary tumor for-
mation.12 Furthermore, when loaded into tumor cells,
a-GalCer inhibited the onset of transplantable tumors, and its
systemic administration slowed down metastatic tumors.13,14
The ability of a-GalCer to induce antigen non-specific rejection
of B16.F10 lung metastases was shown to be IFN-g dependent
and to require activation of iNKT cells followed by NK cell
activation.15
Over the last few years, several clinical trials have been per-
formed in cancer patients either by systemic administration of
a-GalCer or adoptive transfer of a-GalCer-loaded autologous
DCs.16 However, systemic administration of a-GalCer and its
efficacy is hampered due to its insolubility in aqueous media.
Hence, some molecular modifications have been performed to
increase its solubility or DCs have been ex-vivo loaded with
a-GalCer improving in vivo and in vitro iNKT cell responses in
mice and humans.17-21
Delivery of particulate antigens or adjuvants by employing poly
(lactic-co-glycolic acid) (PLGA) NP has proven advantages over
soluble administration such as more efficient uptake, controlled
release and improved immunogenicity.22 Within the context of
NKT cell stimulation, a-GalCer, MPLA and OVA coated PLGA
micro and NP were injected to mice which induced a more robust
and long sustained antigen-specific IgG responses than administra-
tions in solution.23 Similar a-GalCer coated silica microparticles
have shown to be mostly taken up by macrophages and DCs
located in the marginal zone of spleens and CD169+ macrophages
in the lymph nodes of mice.24,25 In addition, a-GalCer coated PLA
particles were demonstrated to prevent iNKT cell anergy occurring
as unresponsiveness to sequential stimulation by a-GalCer.26 Nev-
ertheless, lower in vivo and in vitro NKT cell cytokine responses
were observed with both PLA and PLGA formulations of a-GalCer
than administration in solution.26,27 DEC205 targeted delivery of
a-GalCer loaded PLGA particles to DCs were able to increase
iNKT cell responses and demonstrated increased CD8C T cell
responses against OVA antigen.28 In this study, we used a biological
dose-response assay to quantify the actual amount of PLGA
entrapped a-GalCer to obtain a more precise evaluation of nano-
particle mediated delivery. Using these well-characterized NP we
challenged the co-delivery concept of protein and glycolipid anti-
gens in detail by comparing various combinations of a-GalCer and
full-length OVA. We also for the first time compared different
types of adjuvants by means of in vivo and in vitro immune stimu-
lation potentials: PLGA encapsulated a-GalCer versus more classi-
cal TLR-ligands. We demonstrate that a-GalCer and OVA loaded
PLGA NP are not only superior to TLR-ligands but also induce
both prophylactic and therapeutic responses in the B16.OVA
mousemelanomamodel.
Results
Co-encapsulation of a-GalCer and OVA elicit superior in
vivo stimulation
To determine the in vivo efficacy of a-GalCer on vaccination
induced antigen-specific killing, we compared responses of
OVA and a-GalCer containing NP(OVA+ a-GalCer) with
OVA+ TLR-ligands (R848 and poly I:C) containing NP(OVA+
TLR). Only OVA antigen encapsulating NP served as a control
NP(OVA). The presence of TLR-Ligands within the OVA NP
provided slightly enhanced killing of SIINFEKL peptide-pulsed
syngeneic target cells over control NP (Fig. 1A). In contrast,
when co-encapsulated within the OVA nanoparticles, a-GalCer
was able to generate a significant population of antigen-specific
CTLs and induce the killing of SIINFEKL peptide-pulsed target
cells up to 90 percent (Fig. 1A). TLR-Ligands could not match
these results with even 10 times higher doses (Fig. S1A). Inter-
estingly, administration of the same dose of (1ng) free
a-GalCer mixed with the same amount of (0.66mg) OVA
loaded (NP(OVA)+ free a-GalCer) led to only 40 percent of
specific killing and minimal induction of tetramerC CTLs
(Fig. 1A). Similar results at around 40 percent killing were
obtained with a mixture of NP loaded with a-GalCer alone and
OVA alone (NP(OVA)+ NP(a-GalCer)) and injected at the
same tail vein (Fig. 1A). When OVA NP and free a-GalCer
injected in different veins (NP(OVA)+ free a-GalCer), the
vaccine-induced responses decreased even further, suggesting
that co-encapsulation of a-GalCer and the OVA antigen is cru-
cial for the induction of a full blown CTL activation.
a-GalCer was also able to provide adjuvant functions to
more than one epitope present within the same particle (NP
(OVA+HPV+ a-GalCer)) (Fig. S2A). While the response
against the HPV peptide was less than OVA in the same parti-
cle we did observed a similar killing activity as induced by
another short peptide, SIINFEKL. When co-encapsulated with
a-GalCer and delivered at same molar amounts SIINFEKL
failed to induce comparable results as the full length OVA pro-
tein (Fig. S2A). Next, a group of mice was depleted of the
CD4C cells to question if the reduced response to short peptides
was due to a possible help by CD4+ T cells to full length OVA
protein which also includes MHC II associated peptides. How-
ever, no reduction of cytotoxicity was detected at these mice
indicating the independence of this system from helper T cells
(Fig. S2A).The enhanced stimulatory potential of co-encapsu-
lated OVA+a-GalCer was confirmed by in vivo proliferation of
CD8C T cells derived from OT-I mice and transferred to either
wild-type or CD1d KO mice, the latter incapable of presenting
a-GalCer. In wild-type mice, ~35 percent of the OT-I cells pro-
liferated after vaccination with OVA loaded nanoparticles,
which could not be increased by the co-encapsulation of TLR-
ligands (Fig. 1B). In line with the observed killing capacity, co-
encapsulation of OVA with a-GalCer also led to highest prolif-
eration of OT-I T cells (Fig. 1B). Furthermore, in CD1d KO
mice, lacking the a-GalCer/CD1d presentation pathway, prolif-
erative responses were at baseline levels as observed in WT
mice vaccinated with only OVA loaded NP (Fig. 1B). This find-
ing demonstrates the specificity of the response and that the
observed proliferation is dependent on the a-GalCer/CD1d
presentation pathway. Intriguingly, the a-GalCer in separate
NP was more efficient in inducing proliferation than free
a-GalCer accompanying OVA NP (Fig. 1B).
a-GalCer NP stimulate similar cytokine responses both in
vitro and in vivo
Next, we isolated splenocytes from naive BL/6 or CD1d KO
mice and cultured them with increasing doses of a-GalCer.
Both NP (OVA + a-GalCer) and NP (a-GalCer) induced
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similar levels of IFN-g secretion when compared to free
a-GalCer in solution (Fig. 2A). As expected, no IFN-g was
detected in CD1d KO mice splenocyte cultures supplemented
with either NP (OVA+a-GalCer) or NP (a-GalCer) (Fig. 2A).
Furthermore, even the high-concentrations (128ng) of NP
(OVA+TLR-L) were not able to stimulate IFN-g production
comparable to that of a-GalCer containing nanoparticles. Yet,
they generated high IL-6 levels, demonstrating that the TLR
ligand containing particles were functional since IL-6 produc-
tion is entirely independent of the presence of aGalCer or
CD1d (Fig. 2B). The above mentioned in vitro responses of
splenocytes were also unrelated to the presence of OVA antigen
in the particles because these could neither induce IFN-g nor
IL-6 secretion.
In parallel with our in vitro findings, we could demon-
strate that significant IFN-g serum levels were induced by
injecting 1ng a-GalCer containing NP (Fig. 2C). In accor-
dance with the literature,29 repeated injections of both par-
ticulate and free a-GalCer resulted in lower IFN-g secretion
as a result of iNKT cell anergy (Fig. 2C). Together, these
findings demonstrate that the activity of a-GalCer NP is
entirely CD1d dependent.
We observed lower responses when the free a-GalCer was
diluted with either RPMI or Vehicle (PBS %0.5 Tween) rather
than DMSO (Fig. 2D). Additionally, similar in vitro IL-2 levels
were obtained when OVA+ a-GalCer NP were dissolved by
DMSO to release the encapsulated a-GalCer (Fig. S1B). These
findings suggest that PLGA encapsulation of a-GalCer do not
interfere with its antigenic properties or presentation.
NP(OVA+ a-GalCer) induce long-term protection from
B16-OVA melanoma formation
Next, we probed the prophylactic immunization potential of
different nanoparticles. Mice were vaccinated with NP contain-
ing OVA antigen and 7 d later subcutaneously inoculated
with 1£105 B16.OVA melanoma cells (Fig. 3A). NP(OVA
+a-GalCer) provided protection to a significant proportion of
mice. Much lower protection was observed in mice that
received NP(OVA+TLR-L) (Fig. 3A). Multiple tumor inocula-
tions were performed to test the duration of immune protection
induced by NP(OVA +a-GalCer) vaccination (Fig. 3B).
Whereas all mice of the NP(OVA+TLR-L) group had to be
euthanized due to tumor size limits until day 60, no tumor was
Figure 1. In vivo antigen-specific T cell responses induced by nanoparticles. (A) Mice were vaccinated with indicated nanoparticle combinations and transferred with SIIN-
FEKL peptide-loaded syngeneic target cells and irrelevant peptide-loaded control cells. Primary antigen-specific in vivo killing responses (left) and SIINFEKL H-2Kb tetra-
mer-positive cell percentages (right) obtained by OVA and a-GalCer or TLR-L injections were demonstrated. Results of three independent experiments were pooled. n>
6 for each group (B) OT-I T-cell proliferation induced by nanoparticle administration to wild type naive mice, n=5 (left). Comparison of OVA+ a-GalCer nanoparticle
induced proliferation of OT-I T cells transferred to either CD1d KO or wild-type mice, n=30 (right). Parenthesis indicates encapsulation, $ indicates injection of NP(OVA)
and free a-GalCer to different veins consequently. 0,66ug OVA, 1ng a-GalCer, 143ng R848 and 70ng poly I:C was introduced within NPs. Mean values were shown with
standard error, ns: no significance,  p < .05,  p < .01,  p< .001
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Figure 2. Cytokine responses obtained by nanoparticle encapsulated a-GalCer and TLR-ligands. (A) IFN-g levels of 48h splenocyte cultures with indicated NPs or free
a-GalCer in solution. (B) IL-6 levels of 48h splenocyte cultures with indicated NPs. Splenocytes were isolated from either naive wild-type BL/6 or CD1d KO BL/6 mice (A-B,
n>4). (C) IFN-g serum levels measured 24 h after iv. injections of 1ng a-GalCer either in nanoparticles or free. Vaccinations were repeated 2 times on days 7 and 14, empty
particles were used as a control, n3. Mean values were shown with standard error. (D) IL-2 response curves of DN32D3 NKT cell hybridoma cultured 24h with a-GalCer
loaded BMDCs. a-GalCer was serially diluted in DMSO, RMPI medium or PBS 0.05% tween 20 (Vehicle) and cultured with BMDCs at a range of 25ng-0.01ng/mL. One repre-
sentative graph of three experiments was shown.
Figure 3. Antitumor effects of (OVA+a-GalCer) nanoparticle immunization. (A) Mice were immunized on day 0 with indicated vaccines and B16.OVA cells were subcutane-
ously inoculated on day 7(dotted line). Survival results of two independent experiments were shown. Censored data points were shown with symbols. PBS, n= 7; NP(OVA
+TLR-L), nD8 and NP(OVA+ a-GalCer), nD8. (B) Vaccinations were performed on day 0 and tumors were inoculated on day 7 as in A. NP(OVA+ a-GalCer) group was
re-challenged with tumor cells on day 50 and 78 (dotted line). NP(OVA+TLR-L) n=6, NP(OVA+ a-GalCer) nD8 . (C) Mice were first subcutaneously inoculated with B16.
OVA cells and vaccinations were started individually when each tumor reached 30mm3 and repeated three times weekly. NP(OVA), n=7, Mitv=26mm3; NP(OVA+TLR-L),
n=13, Mitv=33mm3 ; NP(OVA+a-GalCer), n=19, Mitv=33mm3. Data points of mice culled due to early necrosis were censored. Censored data points were shown with
symbols. Mitv: Mean initial tumor volume.  P < .001.(D) Serum samples were collected 24 h after each vaccination of tumor-bearing mice in (C) and IFN-g levels were
determined by ELISA. n=7. Mean results were shown with standard error.
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observed in the NP (OVA+aGalCer) group, even if they were
re-challenged with B16.OVA cells as late as day 50 and 78
(Fig. 3B). Cumulatively, 13 out of 16 animals were tumor free
at the end of 3 independent experiments (Fig. 3A and B). Thus,
antigen and a-GalCer co-encapsulation is capable of generating
a substantial tumor resistance when administered in a protec-
tive setting.
Treatment with NP(OVA+a-GalCer) inhibits the growth of
established B16-OVA tumors
To investigate the therapeutic efficacy of antigen + a-GalCer
co-encapsulation; mice were subcutaneously inoculated with
B16.OVA melanoma cells prior to immunization. The vaccina-
tions were started when each tumor reached ~30–40mm3 and
were repeated three times at weekly intervals.
While NP(OVA) or NP(OVA+TLR-L) could not provide
any survival advantage over PBS injection, NP(OVA
+a-GalCer) significantly inhibited tumor growth and extended
the mean (overall) survival of the mice (Fig. 3C, Fig. S3). At the
same time, we observed a profound iNKT cell anergy with the
mice receiving multiple treatments of NP(OVA +a-GalCer)
(Fig. 3D). Furthermore, experiments demonstrated that even a
single dose of NP(OVA +a-GalCer), containing as little as 1ng
of a-GalCer resulted in a significant delay of tumor growth
(Fig. S3).
Immunofluorescence imaging of tumor specimens demon-
strated increased CD8C T cell infiltration in tumors of mice
treated with NP (OVA+a-GalCer) when compared to mice
treated with NP (OVA+TLR-L) or NP(OVA) (Fig. 4). In paral-
lel with the microscopy results, an increased proportion of
CD3C CD8C NK1.1- cells were detected by flow cytometry in
tumor tissues (Fig. S4A and B). The intra-tumoral CD8+ T cells
were also positive for SIINFEKL tetramer indicating their speci-
ficity against tumor antigen.
Discussion
Induction of long-lasting anticancer T cell responses is one of
the primary objectives of cancer immunotherapy. Both the
limited number of tumor antigens together with their low
immunogenicity form a major obstacle in generating strong
antitumor responses. In an attempt to activate specific compo-
nents of the immune system more directly, platforms have
been developed to encapsulate antigens and adjuvants in
nano-sized particles that enhance antigen-specific T cell
responses.30-33 Targeted delivery of these particles to DC s
have provided even more efficacy.28,34
In the present study, we compared the adjuvanticity of
PLGA encapsulated a-GalCer with that of more classical TLR
ligands in combination with OVA protein. We observed that
a-GalCer served as a much better adjuvant in inducing CD8C
T cell responses when compared to TLR ligand within NPs.
Even though the a-GalCer alone did not take advantage of par-
ticle formulation, the best results were surprisingly obtained
when both antigen (OVA) and a-GalCer are present in the
same NP. In this case, only subtle amounts of antigen and
a-GalCer were enough to stimulate significant antitumor
responses.
Previously, virus-like particles attached with a-GalCer failed
to induce IFN-g secretion when compared soluble a-GalCer.
However, prophylactic vaccination with particulate forms of
Figure 4. Intratumoral T cell infiltration after therapeutic vaccinations. Similar sized tumors were isolated 8 d after first vaccination. Frozen tumor tissues were screened
for CTL infiltration by CD8C (red) and DAPI (Blue) staining by Vectra automated quantitative imaging system. NP(OVA), n=2; NP(OVA+TLR-L), n=4; NP(OVA+a-GalCer),
n=2.
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a-GalCer provided a better protection against B16.gp33 tumor
formation.35 In another study, a-GalCer and OVA loaded DC
derived exosomes were able to control B16.OVA tumor growth
better than soluble a-GalCer and OVA, while at the same time
preventing development of iNKT cell anergy.36 So far, only a
few studies reported on the immunologic or therapeutic antitu-
mor effect of a-GalCer in conjunction with PLGA particles.26-
28 In a study by Thapa et al., it was demonstrated that 500-
1,000nm sized a-GalCer coated PLGA particles induced similar
cytokine responses as the free glycolipid in vitro, whereas the
systemic application induced 10-fold lower IFN-g serum levels
when compared to solubilized a-GalCer.26 Macho Fernandez
et. Al. also reported a similar discrepancy between the efficacy
of soluble versus particulate a-GalCer both in vitro and in vivo,
albeit less pronounced with two times lower IFN-g serum lev-
els.27 In contrast, we find similar cytokine responses with nano-
particle or free a-GalCer both in vitro as in vivo. To carefully
quantify the amounts a-GalCer in nanoparticles, we performed
a biological dose-response assay. In the course of these experi-
ments, we also observed that solvents used in diluting free
a-GalCer could significantly affect its biological availability due
to its insolubility in aqueous media and, therefore, might be
affecting the previous results. We suggest dissolving a–GalCer
in DMSO for free administration and performing a biological
assay to quantify encapsulated amount in NP for a more justi-
fied comparison. Therefore, the discrepancy between our
results and the previous reported studies may be due to the dif-
ferent solvents used in diluting free a-GalCer, different particle
diameters as well as incorrect a-GalCer contents of particles
due to the methods used for quantification.
Previously, Tacken et.al. demonstrated co-encapsulation of
OVA and TLR-ligands in PLGA particles leading to a dramatic
boost of cytotoxic T-cell mediated killing in comparison to
TLR-ligands in solution when mixed with OVA NP.34 Schlosser
et al also made similar observations showing the importance of
co-encapsulation of CpG, poly I:C and SIINFEKL in PLGA par-
ticles.37 We here demonstrate that this holds not only true for
TLR ligands but also for a-GalCer co-encapsulation with OVA,
as it became apparent that the generation of antigen-specific T
cells and killing of antigen-pulsed cells was dramatically
reduced when antigen and a-GalCer were separately injected
into different veins. Similar findings were reported when solu-
ble OVA and a-GalCer were injected at different time points.7
Together, all these results support the notion that co-delivery
of a-GalCer and antigen to the same cell is essential. Although
the underlying mechanism is not entirely clear, MyD88
dependent TLR signaling can selectively increase the cross-pre-
sentation of the phagosomes that contain both antigen and
TLR-ligands, which could contribute to the enhanced responses
resulting from TLR-ligand and antigen co-delivery.38 Such a
sub-cellular selectivity is less likely to be relevant for a-GalCer
co-delivery as this is described to induce DC maturation inde-
pendent of MyD88 down stream signaling.9 On the other hand,
a-GalCer presenting APCs gain a co-stimulatory advantage
also to which CTL trafficking was promoted by an iNKT cell-
mediated CCL17 driven fashion.6,7, 9,39 This cognate licensing
of DCs by iNKT cells may explain the enhanced immune
responses we observed with OVA+ a-GalCer co-encapsulated
NP.7,39 The NP were taken up mostly by F4/80+ macrophages
and to a lesser extend by DCs in the liver and spleen. An
increased iNKT cell expression of CD40L demonstrate the
co-stimulatory cross-talk between APCs and iNKT cells after
nanoparticle vaccinations (Fig. S6A and B).The notion of cog-
nate licensing is supported by our findings that CD40 and
CD86 expressions of APCs were hampered when a-GalCer is
injected in solution instead of NP (Fig. S7).
We hypothesized that the requirement of professional
APCs in processing full-length proteins would ensure a co-
stimulatory signal through CD1d and iNKT cell activation
whereas, if they are released to circulation, short peptides
might be presented by non-APCs which do not express co-
stimulatory molecules and CD1d and lead to a tolerogeneic
response. As expected, SIINFEKL peptide and a -GalCer
loaded particles induced lower levels of specific killing in
comparison to the same molar amount of full-length OVA
protein and a -GalCer introduced within NP (Fig. S2A).
This reduction was not due to loss of a T-cell help provided
by an MHC-II epitope present on full length OVA protein.
However, the same mice demonstrated similar tetramer pos-
itive CTL ratios supporting the tolerogeneic or less activated
phenotype induced by non-professional APCs (Fig. S2B).
Moreover, it is known that SIINFEKL peptide cargo has a
very high-burst release from PLGA particles in one d when
compared to OVA protein which takes d to weeks.40,41 This
low burst-release of full length OVA protein may also ame-
liorate CD8C T cell stimulation as previously published in a
setup with a long OVA peptide.42
The antigen-specific in vivo killing response is an important
prediction of antitumor immune responses. Concordantly,
OVA+a-GalCer nanoparticles provided up to a total protection
from B16.OVA melanoma formation after a single immuniza-
tion, which was persistent for more than two months demon-
strating a substantial memory. Finally, when tested on mice
with already established tumors, OVA+a-GalCer NP exhibited
a significant delay in tumor growth and extended mean sur-
vival. It is of note that these effects were obtained despite a pro-
found iNKT cell anergy and without any OT-I T cell transfer
and totally due to priming of naive T cells and generation of
OVA-specific CTLs which were capable of infiltrating to the
tumor sites corresponding to the extended stabilization of
tumor volumes. The described CD1d-iNKT cell driven system
exploited by nanoparticle delivery of the low dose a-GalCer do
not require but instead replace the CD4C T cell help. Addition-
ally, CD154 positivity of iNKT cells was higher than basal levels
until day 9 after one vaccination which may still provide
co-stimulation despite the lack of IFN-y secretion. Moreover,
cytotoxic immune responses may be obtained simultaneously
to more than one antigen at the same time which grants a wider
therapeutic potential of various stimulants and (patient-spe-




PLGA (Resomer RG 502 H, lactide/glycolide molar ratio 48:52
to 52:48) was purchased from Boehringer Ingelheim
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(Germany). Solvents for PLGA preparation (dichloromethane)
were obtained from Merck (Germany). Polyvinyl alcohol
(PVA) was obtained from Sigma (The Netherlands). R848 was
from Enzo Life Sciences poly I:C from Sigma-Aldrich, and
endotoxin-free OVA from Hyglos. OVA (257 – 264) SIINFEKL
and HPV16 E7(49–57) obtained from Anaspec. a-GalCer was
purchased from Funakoshi Co. Ltd. Dimethyl sulfoxide
(DMSO) 99.9% and Tween 20 was obtained from Sigma (The
Netherlands). Atto647N was obtained from Atto-tec GmbH.
RPMI 1640 medium (Life Technologies Inc..). PE-conjugated
CD3, APC-Cy7 conjugated CD45.2 (BD Biosciences), PerCP
conjugated CD8Ca (Biolegend), and APC-conjugated H2-Kb/
SIINFEKL-Tetramer (Sanquin), PE conjugated CD1d-
a-GalCer dextramer (Immudex),FITC conjugated CD11b, PE/
Cy7 conjugated CD11c, Alexa488 conjugated F4/80 and NK1.1
(Biolegend), PE/Cy7 conjugated CD154 (Biolegend), Celltrace
CFSE, Celltrace- violet and Celltrace red (Life technologies
Inc.), were used in flow cytometric cell staining. For the deple-
tion studies, anti-mouse CD4C antibody clone GK1.5 was
obtained from BioXcell. For the detection of CD4C populations
PerCP/Cy5.5 conjugated anti-mouse CD4C antibody clone
RM4-4 was obtained from Biolegend.
Nanoparticle synthesis
PLGA NP with entrapped OVA alone or in combination with
R848, poly I:C or a-GalCer were prepared using an o/w emul-
sion and solvent evaporation–extraction method as previously
described.33 In brief, 100 mg of PLGA in 3 mL of dichlorome-
thane containing, 5 mg OVA, 1.6mg SIINFEKL or HPV16 E7,
2 mg poly I:C, 0.5 mg R848 or 0.1 mg a-GalCer and 0.5mg
Atto647N was added dropwise to 25mL of aqueous 2% polyvi-
nyl alcohol and emulsified for 120 seconds using a digital soni-
cator from Branson Ultrasonics (Danbury, CT). The solvent
was evaporated overnight at 4C and NP were collected by cen-
trifugation at 14.000 rpm for 20 min, washed six times with dis-
tilled water and lyophilized.
Nanoparticle characterization
The size and polydispersity index of the NP was analyzed by
dynamic light scattering using a Zetasizer Nano ZS (Malvern
Instruments Ltd, Malvern,UK) as described before.33 Encapsu-
lation efficiency for OVA was determined by measuring the
protein content of digested particles using Coomassie Plus Pro-
tein Assay Reagent (Pierce) according to the manufacturer’s
protocol. Encapsulation of SIINFEKL peptide was determined
by measuring protein content of DMSO dissolved particles
using CBQCA protein quantification kit (Life Technologies)
according to the manufacturer’s protocol. Concentration of
R848 in NP was determined using a high-performance liquid
chromatography (HPLC) system (Shimadzu, Kyoto, Japan)
equipped with a Supelcosil lC-18-T column (150 mm £
4.6 mm) with a constant flow rate of 1 mL/min and detection
at a wavelength of 220nm. R848 was extracted from NP by dis-
solving 1 mg NP in 100ml DMSO followed by centrifugation at
14.000 rpm for 10 minutes. 25mL supernatant or standard was
assayed by HPLC. The quantity of R848 and was calculated by
interpolation from the standard curves. Entrapment efficiency
for poly I:C was determined by measuring the absorption of
digested particles or standard on a Nanodrop 2,000 (Thermo
Scientific) the amount of poly I:C was calculated by interpola-
tion from the standard curves. Nanoparticle characteristics are
demonstrated at Table S1.
BMDC/DN32 cultures and quantification of a-GalCer
encapsulation
For standards, stock a-GalCer was dissolved 1mg/mL in DMSO
(99.9%) and serially diluted in DMSO(99.9%), RMPI 1640
medium or vehicle (PBS, 0.05% tween 20). PLGA NP were bro-
ken down with DMSO for 15 min. at 80C. Both dissolved
PLGA and standards were further diluted 1/1,000 in complete
RPMI medium and cultured with 5£104 BMDCs. 24 h later
supernatants were aspirated, and 105 DN32.D3 mouse iNKT
hybridoma cells were added to the culture. IL-2 levels were
determined by ELISA after 24-h incubation. The a-GalCer con-
tents of dissolved PLGA NP were determined according to the
standard curve of DMSO dilution obtained from the same
experiment.
Mice and tissue
Wild-type C57BL/6JRccHsd (Harlan) and OT-I C57BL/6-Tg
(TcraTcrb)1100Mjb/Crl (Charles River) mice were main-
tained under specific pathogen-free conditions at the Cen-
tral Animal Laboratory (Nijmegen, the Netherlands).
CD1d¡/¡ (iNKT cell-deficient) C57BL/6 mice were bred
and maintained at the animal facility of the John Radcliffe
Hospital, Oxford. Drinking water and food were provided
ad libitum. The experiments were performed according to
guidelines for animal care of the Nijmegen Animal Experi-
ments Committee and the Animal Ethics Committee of
Cancer Research UK and the United Kingdom Home Office
and in accordance with the ethical standards described in
the declaration of Helsinki. Spleens were isolated under
sterile conditions and stored at 4C in RPMI 1640 medium
suplemented with 100 U/mL penicilium and 100 mg/mL
streptomycin until processing for maximally 2 h. Spleen
cells were meshed through a 100um cell strainer by using a
syringe plunger. Cell suspension was spun at 400xg for
5 min and resuspended in 3mL of 1x ammonium chloride
solution for the lysis of erythrocytes. After 5 min of incuba-
tion at room temperature cells were washed with 20mL of
PBS 2 times. Fresh materials were used in all experiments.
Cells were counted by a hemacytometer. Fixable Viability
Dye eFluor® 780 (ebioscience) or zombie violet (Biolegend)
dyes were used to exclude dead cells in flow cytometry
applications.
In vitro stimulation by PLGA nanoparticles
2£105 splenocytes isolated from either na€ıve wild-type C57BL/
6 mice or CD1d knockout C57BL/6 mice were cultured with
graded doses of NP or free a-GalCer in complete RPMI 1,640
medium supplemented with 10% FBS, 2.1 mM ultra-glutamine
and 50 mM 2-Mercaptoethanol. The serum is routinely tested
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for assay performance. 48-h culture supernatants were screened
for IFN-g and IL-6 by ELISA.
In vivo cytotoxicity assay and cytokine analysis
NPs re-suspended in sterile PBS were injected into the tail veins
of C57Bl/6 mice. The introduced NPs were contained 0,66mg
OVA, 1ng a-GalCer, 143ng R848, and 70ng poly I:C. All
groups have injected with same doses for the same components
unless mentioned otherwise. Some animals were injected with
free a-GalCer and NP(OVA) on opposite tail veins conse-
quently within 1 min. Some animals were injected with PBS as
a negative control. Blood samples were collected 24 h after vac-
cinations in anticoagulant free tubes’ kept at room temperature
for 1h and serum was isolated by centrifugation. Serum samples
were stored at ¡20C. IFN-g levels of serum samples were
determined by ELISA. Seven to eight d after IV injections, sple-
nocytes were prepared from wild-type C57Bl/6 mice and
divided into two groups. Cells were pulsed with either 1 mg/mL
relevant OVA-SIINFEKL peptide or 1 mg/mL irrelevant E1A
peptide and labeled with 5 mM Celltrace-violet (relevant OVA)
or 5 mM CFSE (irrelevant E1A) respectively. In order to asses
killing of two epitopes by NP(OVA+HPV+ a-GalCer) vaccina-
tions, cells were divided into three equal groups and pulsed
with either 1 mg/mL relevant OVA-SIINFEKL peptide, 1 mg/
mL relevant HPV16 E7 or 1 mg/mL irrelevant E1A peptide and
labeled with 5 mM CFSE (relevant OVA), 5 mM Celltrace-violet
(relevant HPV16 E7) or 5 mM Celltrace-red (irrelevant E1A)
respectively. Stained cells were mixed and 10 £ 106 total cell
mixtures were injected intravenously into the immunized mice.
The following day, splenocytes were isolated, stained with CD3,
CD8C, CD4C, CD154 SIINFEKL tetramer and CD1d-aGalCer
dextramer and cell percentages were measured by FACS Verse
(BD) flow cytometer. FlowJo X software was used for analyzes
of cytometry data. The PBS vaccinated mice were used to deter-
mine control ratio for each experiment.
Killing was measured by flow cytometry using the following
formula:
Ratio D Irrelevant Percentage : Relevant Percentage
Percent Specific Lysis D [1-(PBS vaccinated control ratio/Experi-
mental ratio)] £ 100
For in vivo depletion of CD4C cells, a group of mice received
500mg/mouse of anti-CD4C (GK1.5) antibody by ip. route 2 d
before vaccination with NP(OVA+aGalCer). Antibody admin-
istration was repeated on days 1, 4 and 7 with 200 mg/mouse
doses. Total depletion of CD4C T cells and iNKT cells were
confirmed by FACS staining.
In vivo proliferation assay
OT-I mice splenocytes were depleted of CD1d expressing cells
by B220, CD11b and CD11c magnetic beads according to the
manufacturer protocol (Miltenyi Biotec). Remaining cells
were stained with 5 mM CFSE and 3£106 transferred to either
naive or CD1d KO mice by IV vaccination. Twenty four h later
mice were vaccinated with NPs. Four d later mice were eutha-
nized, and mononuclear cells were isolated from spleens.
Proliferations of CD3+ CD8C cells were determined by reduc-
tion of CFSE intensity.
In vivomaturation assay and fluorescent particle tracking
Naive BL/6 mice were injected with either NP(OVA+TLR-L);
NP(OVA+ a-GalCer) or NP(OVA)+ free a-GalCer in the
opposite vein. 0.66mg OVA and 1ng of a-GalCer doses were
applied as used with in vivo cytotoxicity and proliferation
assays. Sixteen h later mice were culled, and splenocytes were
analyzed by flow cytometry. Red pulp macrophages were
selected as CD11bC, F4/80C; B cells as B220C,CD19C; CD8aC
DCs as CD11chi, B220-, CD8aC. CD40 and CD86 expression
patterns were compared.
CD154 (CD40L) expression of iNKT cells were checked 1, 5
and 9 d after vaccinations with NP(OVA+ a-GalCer) by stain-
ing liver and spleen cell suspensions with CD1d- a-GalCer
dextramer and CD154 antibody. An isotype staining and non-
vaccinated mice cells were used as control in all experiments.
Sixteen h after iv.injection of 2mg NP(OVA+ a-GalCer
+Atto647N) particles, mice were culled and spleen and liver
cells were checked for Atto647 fluorescence by flow cytometry.
CD11b, CD11c, F4/80 and CD8C antibodies were also used to
discriminate major antigen presenting cells.
Tumor models
In order to assess protection from tumor onset, mice were vac-
cinated with PLGA NP containing 0.66mg OVA alone or
together with 1ng a-GalCer or 143ng R848 and 70ng poly I:C
in PBS. One-week later mice were inoculated with 1£105 B16.
OVA cells on their hind flank region and tumor development
was monitored daily. For one independent experiment,
additional tumor cell challenges were performed to OVA+
a-GalCer immunized group on days 50 and 2.5£105 cells on
day 78. For therapeutic model, mice were first inoculated with
1£105 B16.OVA cells in their hind flank region. Vaccinations
were started when tumor size of a mouse reach 30mm3 (10–
23 d after tumor cell inoculation). Allocations were performed
so that all groups had similar mean tumor volumes. Vaccina-
tions were repeated three times weekly for some groups. The
animals were euthanized when tumors reach 1500mm3 volume.
Mice with ulcerative tumors were culled due to ethical reasons
and data points were censored.
For the detection of T cell infiltration to the tumor site, some
mice with similar tumor sizes were sacrificed 8 d after first vac-
cination. Single cell suspensions were obtained from tumors
after collagenase/DNAse treatment and consequent 1.077g/mL
density gradient separation by ficoll. Leukocytes were gated by
CD45.2 positivity. NK1.1, CD3, CD4C, CD8C antibodies and
SIINFEKL tetramer were used to determine T cell proportions.
Immunofluorescence staining
Tumors were isolated 24 h after second vaccination, frozen in
liquid nitrogen and stored at ¡80 C. Cryosections of 10mm
thickness were placed on glass slides and fixed with 4% formal-
dehyde PBS. Blocking of slides was performed with 5% normal
goat serum following staining of rat anti-mouse CD8C antibody
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and consequently with A-647 conjugated goat anti-rat second-
ary antibody. DAPI was used as a nuclear counterstain. Stained
slides were loaded onto the slide scanner of Vectra® automated
quantitative multispectral imaging system. Nuance 3.0.0 soft-
ware was used to build a spectral library in order to unmix the
autofluorescence background and subsequently the unmixed
imaged were loaded into the inForm software for cellular seg-
mentation and quantitative analysis of CD8C cells density in
the tumor tissue.
Statistical analysis
Mann–Whitney test was used to compare two different groups
in Figs. 1 and 2. Log-Rank(Mantel-Cox) tests were used to
compare survival curves on Figs. 3 and 4. Graph Pad Prism v6
was used in all statistical analyzes. Raw data can be provided
per request. These studies (or specific parts thereof) were per-
formed using established protocols. These studies were con-
ducted in a laboratory that operates under good laboratory
principles. These studies were performed using standardizied
assays.
Disclosure of potential conflicts of interest
No potential conflict of interest was disclosed.
Acknowledgments
The authors present their gratitude to Melissa Wassink and Annemarie de
Graaf for technical assistance.
Funding
This work was supported by ERC advanced grant PATHFINDER (269019)
and KWO award KUN2009-4402 from the Dutch Cancer Society (to CF).
J. Tel is recipient of NWO Veni grant 863.13.024. Carl G. Figdor is recipi-
ent of an NWO Spinoza award.
References
1. Platzer B, Stout M, Fiebiger E. Antigen cross-presentation of immune
complexes. Front Immunol 2014; 5:140; PMID:24744762; http://dx.
doi.org/10.3389/fimmu.2014.00140
2. Andersen BM, Ohlfest JR. Increasing the efficacy of tumor cell vac-
cines by enhancing cross priming. Cancer Lett 2012; 325:155-64;
PMID:22809568; http://dx.doi.org/10.1016/j.canlet.2012.07.012
3. Brennan PJ, Brigl M, Brenner MB. Invariant natural killer T cells: an
innate activation scheme linked to diverse effector functions. Nat Rev
Immunol 2013; 13:101-17; PMID:23334244; http://dx.doi.org/
10.1038/nri3369
4. Carreno LJ, Kharkwal SS, Porcelli SA. Optimizing NKT cell ligands as
vaccine adjuvants. Immunotherapy 2014; 6:309-20; PMID:24762075;
http://dx.doi.org/10.2217/imt.13.175
5. Terabe M, Berzofsky JA. The immunoregulatory role of type I and
type II NKT cells in cancer and other diseases. Cancer Immunol
Immunother 2014; 63:199-213; PMID:24384834; http://dx.doi.org/
10.1007/s00262-013-1509-4
6. Fujii S, Liu K, Smith C, Bonito AJ, Steinman RM. The linkage of
innate to adaptive immunity via maturing dendritic cells in vivo
requires CD40 ligation in addition to antigen presentation and CD80/
86 costimulation. J Exp Med 2004; 199:1607-18; PMID:15197224;
http://dx.doi.org/10.1084/jem.20040317
7. Hermans IF, Silk JD, Gileadi U, Salio M, Mathew B, Ritter G, Schmidt
R, Harris AL, Old L, Cerundolo V. NKT cells enhance CD4C and
CD8C T cell responses to soluble antigen in vivo through direct inter-
action with dendritic cells. J Immunol 2003; 171:5140-7;
PMID:14607913; http://dx.doi.org/10.4049/jimmunol.171.10.5140
8. Matsuda JL, Mallevaey T, Scott-Browne J, Gapin L. CD1d-restricted
iNKT cells, the ’Swiss-Army knife’ of the immune system. Curr Opin
Immunol 2008; 20:358-68; PMID:18501573; http://dx.doi.org/
10.1016/j.coi.2008.03.018
9. Fujii S, Shimizu K, Smith C, Bonifaz L, Steinman RM. Activation of
natural killer T cells by a-galactosylceramide rapidly induces the full
maturation of dendritic cells in vivo and thereby acts as an adjuvant
for combined CD4C and CD8C T cell immunity to a coadministered
protein. J Exp Med 2003; 198:267-79; PMID:12874260; http://dx.doi.
org/10.1084/jem.20030324
10. Gonzalez-Aseguinolaza G, Van Kaer L, Bergmann CC, Wilson JM,
Schmieg J, Kronenberg M, Nakayama T, Taniguchi M, Koezuka Y,
Tsuji M. Natural killer T cell ligand a-galactosylceramide enhan-
ces protective immunity induced by malaria vaccines. J Exp Med
2002; 195:617-24; PMID:11877484; http://dx.doi.org/10.1084/
jem.20011889
11. Silk JD, Hermans IF, Gileadi U, Chong TW, Shepherd D, Salio M,
Mathew B, Schmidt RR, Lunt SJ, Williams KJ et al. Utilizing the adju-
vant properties of CD1d-dependent NK T cells in T cell-mediated
immunotherapy. J Clin Invest 2004; 114:1800-11; PMID:15599405;
http://dx.doi.org/10.1172/JCI200422046
12. Hayakawa Y, Rovero S, Forni G, Smyth MJ. Alpha-galactosylceramide
(KRN7000) suppression of chemical- and oncogene-dependent carci-
nogenesis. Proc Natl Acad Sci U S A 2003; 100:9464-9;
PMID:12867593; http://dx.doi.org/10.1073/pnas.1630663100
13. Shimizu K, Goto A, Fukui M, Taniguchi M, Fujii S. Tumor cells
loaded with a-galactosylceramide induce innate NKT and NK cell-
dependent resistance to tumor implantation in mice. J Immunol 2007;
178:2853-61; PMID:17312129; http://dx.doi.org/10.4049/
jimmunol.178.5.2853
14. Schmieg J, Yang G, Franck RW, Tsuji M. Superior protection against
malaria and melanoma metastases by a C-glycoside analogue of the
natural killer T cell ligand a-Galactosylceramide. J Exp Med 2003;
198:1631-41; PMID:14657217; http://dx.doi.org/10.1084/
jem.20031192
15. Smyth MJ, Crowe NY, Pellicci DG, Kyparissoudis K, Kelly JM,
Takeda K, Yagita H, Godfrey DI. Sequential production of inter-
feron-gamma by NK1.1(+) T cells and natural killer cells is essen-
tial for the antimetastatic effect of a-galactosylceramide. Blood
2002; 99:1259-66; PMID:11830474; http://dx.doi.org/10.1182/
blood.V99.4.1259
16. Salio M, Silk JD, Jones EY, Cerundolo V. Biology of CD1- and MR1-
restricted T cells. Annu Rev Immunol 2014; 32:323-66;
PMID:24499274; http://dx.doi.org/10.1146/annurev-immunol-
032713-120243
17. Liu Y, Goff RD, Zhou D, Mattner J, Sullivan BA, Khurana A, Cantu C
3rd, Ravkov EV, Ibegbu CC, Altman JD et al. A modified a-galactosyl
ceramide for staining and stimulating natural killer T cells. J Immunol
Methods 2006; 312:34-9; PMID:16647712; http://dx.doi.org/10.1016/j.
jim.2006.02.009
18. Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, Peters M, von
Blomberg BM, Scheper RJ, van der Vliet HJ et al. A phase I study of
the natural killer T-cell ligand a-galactosylceramide (KRN7000) in
patients with solid tumors. Clin Cancer Res 2002; 8:3702-9;
PMID:12473579
19. Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji
M, Iizasa T, Nakayama T, Taniguchi M, Fujisawa T. A phase I study
of a-galactosylceramide (KRN7000)-pulsed dendritic cells in patients
with advanced and recurrent non-small cell lung cancer. Clin Cancer
Res 2005; 11:1910-7; PMID:15756017; http://dx.doi.org/10.1158/
1078-0432.CCR-04-1453
20. Chang DH, Osman K, Connolly J, Kukreja A, Krasovsky J, Pack M,
Hutchinson A, Geller M, Liu N, Annable R et al. Sustained expansion
of NKT cells and antigen-specific T cells after injection of a-galacto-
syl-ceramide loaded mature dendritic cells in cancer patients. J Exp
ONCOIMMUNOLOGY e1068493-9
Med 2005; 201:1503-17; PMID:15867097; http://dx.doi.org/10.1084/
jem.20042592
21. Fujii S, Shimizu K, Kronenberg M, Steinman RM. Prolonged IFN-
gamma-producing NKT response induced with a-galactosylceramide-
loaded DCs. Nat Immunol 2002; 3:867-74; PMID:12154358; http://dx.
doi.org/10.1038/ni827
22. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Preat V.
PLGA-based nanoparticles: an overview of biomedical applications. J
Control Release 2012; 161:505-22; PMID:22353619; http://dx.doi.org/
10.1016/j.jconrel.2012.01.043
23. Bershteyn A, Hanson MC, Crespo MP, Moon JJ, Li AV, Suh H, Irvine
DJ. Robust IgG responses to nanograms of antigen using a biomimetic
lipid-coated particle vaccine. J Control Release 2012; 157:354-65;
PMID:21820024; http://dx.doi.org/10.1016/j.jconrel.2011.07.029
24. Barral P, Polzella P, Bruckbauer A, van Rooijen N, Besra GS, Cerun-
dolo V, Batista FD. CD169(+) macrophages present lipid antigens to
mediate early activation of iNKT cells in lymph nodes. Nat Immunol
2010; 11:303-12; PMID:20228797; http://dx.doi.org/10.1038/ni.1853
25. Barral P, Sanchez-Nino MD, van Rooijen N, Cerundolo V, Batista FD.
The location of splenic NKT cells favours their rapid activation by
blood-borne antigen. EMBO J 2012; 31:2378-90; PMID:22505026;
http://dx.doi.org/10.1038/emboj.2012.87
26. Thapa P, Zhang G, Xia C, Gelbard A, Overwijk WW, Liu C, Hwu P,
Chang DZ, Courtney A, Sastry JK et al. Nanoparticle formulated
a-galactosylceramide activates NKT cells without inducing anergy.
Vaccine 2009; 27:3484-8; PMID:19200815; http://dx.doi.org/10.1016/
j.vaccine.2009.01.047
27. Macho Fernandez E, Chang J, Fontaine J, Bialecki E, Rodriguez F,
Werkmeister E, Krieger V, Ehret C, Heurtault B, Fournel S et al. Acti-
vation of invariant Natural Killer T lymphocytes in response to the
a-galactosylceramide analogue KRN7000 encapsulated in PLGA-
based nanoparticles and microparticles. Int J Pharm 2012; 423:45-54;
PMID:21575695; http://dx.doi.org/10.1016/j.ijpharm.2011.04.068
28. Macho-Fernandez E, Cruz LJ, Ghinnagow R, Fontaine J, Bialecki E,
Frisch B, Trottein F, Faveeuw C. Targeted Delivery of a-Galactosylcer-
amide to CD8alpha+ dendritic cells optimizes type I NKT cell-based
antitumor responses. J Immunol 2014; 193:961-9; PMID:24913977;
http://dx.doi.org/10.4049/jimmunol.1303029
29. Iyoda T, Ushida M, Kimura Y, Minamino K, Hayuka A, Yokohata S,
Ehara H, Inaba K. Invariant NKT cell anergy is induced by a strong
TCR-mediated signal plus co-stimulation. Int Immunol 2010; 22:905-
13; PMID:21118907; http://dx.doi.org/10.1093/intimm/dxq444
30. DiwanM, Elamanchili P, LaneH,Gainer A, Samuel J. Biodegradable nano-
particle mediated antigen delivery to human cord blood derived dendritic
cells for induction of primary T cell responses. J Drug Target 2003; 11:495-
507; PMID:15203918; http://dx.doi.org/10.1080/10611860410001670026
31. Zhang Z, Tongchusak S, Mizukami Y, Kang YJ, Ioji T, Touma M,
Reinhold B, Keskin DB, Reinherz EL, Sasada T. Induction of anti-
tumor cytotoxic T cell responses through PLGA-nanoparticle medi-
ated antigen delivery. Biomaterials 2011; 32:3666-78;
PMID:21345488; http://dx.doi.org/10.1016/j.biomaterials.2011.01.067
32. Hamdy S, Molavi O, Ma Z, Haddadi A, Alshamsan A, Gobti Z, Elhasi
S, Samuel J, Lavasanifar A. Co-delivery of cancer-associated antigen
and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent
CD8C T cell-mediated anti-tumor immunity. Vaccine 2008; 26:5046-
57; PMID:18680779; http://dx.doi.org/10.1016/j.vaccine.2008.07.035
33. Cruz LJ, Tacken PJ, Fokkink R, Joosten B, Stuart MC, Albericio F,
Torensma R, Figdor CG. Targeted PLGA nano- but not microparticles
specifically deliver antigen to human dendritic cells via DC-SIGN in
vitro. J Control Release 2010; 144:118-26; PMID:20156497; http://dx.
doi.org/10.1016/j.jconrel.2010.02.013
34. Tacken PJ, Zeelenberg IS, Cruz LJ, van Hout-Kuijer MA, van de Glind
G, Fokkink RG, Lambeck AJ, Figdor CG. Targeted delivery of TLR
ligands to human and mouse dendritic cells strongly enhances adju-
vanticity. Blood 2011; 118:6836-44; PMID:21967977; http://dx.doi.
org/10.1182/blood-2011-07-367615
35. McKee SJ, Young VL, Clow F, Hayman CM, Baird MA, Hermans IF,
Young SL, Ward VK. Virus-like particles and a-galactosylceramide
form a self-adjuvanting composite particle that elicits anti-tumor
responses. J Control Release 2012; 159:338-45; PMID:22386518;
http://dx.doi.org/10.1016/j.jconrel.2012.02.015
36. Gehrmann U, Hiltbrunner S, Georgoudaki AM, Karlsson MC, Nas-
lund TI, Gabrielsson S. Synergistic induction of adaptive antitumor
immunity by codelivery of antigen with a-galactosylceramide on exo-
somes. Cancer Res 2013; 73:3865-76; PMID:23658368; http://dx.doi.
org/10.1158/0008-5472.CAN-12-3918
37. Schlosser E, Mueller M, Fischer S, Basta S, Busch DH, Gander B,
Groettrup M. TLR ligands and antigen need to be coencapsulated into
the same biodegradable microsphere for the generation of potent cyto-
toxic T lymphocyte responses. Vaccine 2008; 26:1626-37;
PMID:18295941; http://dx.doi.org/10.1016/j.vaccine.2008.01.030
38. Nair-Gupta P, Baccarini A, Tung N, Seyffer F, Florey O, Huang Y,
Banerjee M, Overholtzer M, Roche PA, Tampe R. TLR signals induce
phagosomal MHC-I delivery from the endosomal recycling compart-
ment to allow cross-presentation. Cell 2014; 158:506-21;
PMID:25083866; http://dx.doi.org/10.1016/j.cell.2014.04.054
39. Semmling V, Lukacs-Kornek V, Thaiss CA, Quast T, Hochheiser K,
Panzer U, Rossjohn J, Perlmutter P, Cao J, Godfrey DI et al. Alterna-
tive cross-priming through CCL17-CCR4-mediated attraction of
CTLs toward NKT cell-licensed DCs. Nat Immunol 2010; 11:313-20;
PMID:20190758; http://dx.doi.org/10.1038/ni.1848
40. Lee YR, Lee YH, Im SA, Kim K, Lee CK. Formulation and characteri-
zation of antigen-loaded PLGA Nanoparticles for efficient cross-prim-
ing of the antigen. Immune Netw 2011; 11:163-8; PMID:21860609;
http://dx.doi.org/10.4110/in.2011.11.3.163
41. Fischer S, Schlosser E, Mueller M, Csaba N, Merkle HP, Groettrup M,
Gander B. Concomitant delivery of a CTL-restricted peptide antigen
and CpG ODN by PLGA microparticles induces cellular immune
response. J Drug Target 2009; 17:652-61; PMID:19622019; http://dx.
doi.org/10.1080/10611860903119656
42. Silva AL, Rosalia RA, Sazak A, Carstens MG, Ossendorp F, Oos-
tendorp J, Jiskoot W. Optimization of encapsulation of a synthetic
long peptide in PLGA nanoparticles: low-burst release is crucial
for efficient CD8(+) T cell activation. Eur J Pharm Biopharm
2013; 83:338-45; PMID:23201055; http://dx.doi.org/10.1016/j.ejpb.
2012.11.006
e1068493-10 Y. D€OLEN ET AL.
